Amphastar enters $2.2M R&D agreement with related party Hanxin for insulin cell banks

Amphastar Pharmaceuticals, Inc.

Agreement with Nanjing Hanxin to develop Recombinant Human Insulin Research Cell Banks (RCBs) and provide exclusive worldwide license.
Total cost capped at ~$2.2M; initial payment ~$0.2M; payments in Chinese yuan.
Related party: CEO Jack Zhang & Chairman Mary Luo family own majority of Hanxin; approved by independent Audit Committee.
Agreement term three years; Amphastar owns all title to RCBs and related IP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.